|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,963.75 GBX | +0.11% |
|
-1.03% | +7.56% |
| 05:59am | GSK Says Jemperli Poised to Transform Rectal Cancer Care After Positive Interim Trial Results | MT |
| 05:09am | GSK Says Mid-Stage Trial of Jemperli Met Main Goal in Rectal Cancer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 105B | |||||
| 1,060B | |||||
| 619B | |||||
| 438B | |||||
| 333B | |||||
| 282B |
- Stock Market
- Stocks
- GSK Stock
- Charts GSK plc
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
